Results 41 to 50 of about 1,228 (155)

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance [PDF]

Postępy Mikrobiologii, 2021
The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj   +2 more sources

The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology, 2022
Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane library, Web of Science, and ...
Rong He, Fei Lin, Fei Lin, Bin Yu, Jingyue Qiu, Lingli Zheng   +5 more
doaj   +1 more source

In vitro activity of delafloxacin and aztreonam against clinical Pseudomonas aeruginosa isolates

, 2022
Diese Studie befasst sich mit der in vitro Aktivität von Aztreonam und Delafloxacin, sowohl alleine als auch in Kombination, in zehn pan-empfindlichen Pseudomonas aeruginosa Isolaten.
Straub, Corinna
core   +3 more sources

In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance [PDF]

Antimicrobial Agents and Chemotherapy, 2016
ABSTRACT We evaluated the in vitro activity of delafloxacin against a panel of 117 Neisseria gonorrhoeae strains, including 110 clinical isolates collected from 2012 to 2015 and seven reference strains, compared with the activities of seven antimicrobials currently or previously ...
Olusegun O. Soge, Stephen J. Salipante, David No, Erin Duffy, Marilyn C. Roberts   +4 more
openaire   +2 more sources

In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone

Journal of Ophthalmic Inflammation and Infection, 2020
Background To assess the in-vitro efficacy of delafloxacin, a new fourth generation fluoroquinolone, against Staphylococcus vitreous isolates from patients with clinically diagnosed endophthalmitis.
Kenneth C. Fan, James Lin, Nicolas A. Yannuzzi, Hasenin Al-Khersan, Nimesh A. Patel, Jorge Maestre-Mesa, Mustafa Zaidi, Darlene Miller, Harry W. Flynn   +8 more
doaj   +1 more source

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model

Antibiotics, 2023
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and
Vaughn D. Craddock, Evan L. Steere, Hannah Harman, Nicholas S. Britt   +3 more
doaj   +1 more source

The efficacy and adverse events of delafloxacin for treating acute bacterial skin and skin structure infections: A systematic review and meta-analysis

Journal of Pharmacy and Bioallied Sciences, 2020
Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity and mortality in hospitalized patients and outpatients as well.
Syed Bilal Tanvir, Syed Saad Bin Qasim, Joe Latimer, Zeeshan Qamar, Fayez Hussain Niazi   +4 more
doaj   +1 more source

Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials

Saudi Pharmaceutical Journal, 2022
Background: This review aimed to conduct an indirect comparison using a Bayesian network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of delafloxacin versus other single antibiotic regimens for the empiric ...
Abdullah A. Alhifany, Nisrin Bifari, Yasser Alatawi, Saad U. Malik, Thamer A. Almangour, Ali F. Altebainawi, Thamir M. Alshammari, Amal F. Alotaibi, Ahmad J. Mahrous, Fahad S. Alshehri, Ejaz Cheema   +10 more
doaj   +1 more source

Clinical review of delafloxacin: a novel anionic fluoroquinolone [PDF]

Journal of Antimicrobial Chemotherapy, 2018
Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in ...
Bryan T Mogle, Jeffrey M Steele, Stephen J Thomas, KarenBeth H Bohan, Wesley D Kufel   +4 more
openaire   +2 more sources

Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial

International Journal of Infectious Diseases, 2020
Objectives: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP).
Sandra McCurdy, Ashley Nenninger, Amanda Sheets, Kara Keedy, Laura Lawrence, Megan Quintas, Sue Cammarata   +6 more
doaj   +1 more source